logo-grupo-sur

XXIV SADI Congress 2024

This important event, which has been taking place since 2000, is undoubtedly the most important event in the field of infectious diseases in our country.

Read More »
7 October, 2024
Load More
Instagram Facebook Linkedin

Grupo Sur Investigación Clínica
® Todos los derechos reservados 2021-2026

Sitio web y comunicación desarrollada por 

Logo Soon Branding (1)
Active Studies - Infectology

C1091009 (BEATRIX)

Phase III, randomized, double-blind, placebo-controlled trial to evaluate the safety, tolerability and immunogenicity of a multivalent Group B Streptococcus vaccine in healthy pregnant women and their babies.

Be a Volunteer. For more information, click here.

D9185C00001 (TILIA)

Phase III, multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of Tozorakimab (MEDI3506) in patients hospitalized for viral pulmonary infection requiring supplemental oxygen.

Prospective and observational study in adult patients hospitalized with acute respiratory infection in Argentina with a focus on Respiratory Syncytial Virus.

C4771002 (BEETHOVEN)

Phase 3, randomized, placebo-controlled, double-blind study to evaluate the efficacy, safety and tolerability of a Clostridioides difficile vaccine in adults aged 65 years or older.

Be a Volunteer. For more information, click here.

C5091017

An interventional efficacy and safety, phase 3, double-blind, 2-arm study to investigate orally administered ibuzatrelvir compared with placebo in non-hospitalized symptomatic adult and adolescent participants with covid-19 who are at high risk of progressing to severe illness.

Be a Volunteer. For more information, click here.

STRIVE 002

Observational Study of Adults Hospitalized with Acute Infection.

Completed Studies - Infectology

RECLAIM
A phase 3, multicenter, randomized, double-blind study to Evaluate the safety and efficacy of Contezolid acefosamil and Contezolid compared to Linezolid Administered Intravenously and Orally to Adults with Moderate or Severe Diabetic Foot Infections.

SPR994-305
A Phase 3, randomized, double-blind, double-dummy, multicenter, multinational study to assess the efficacy and safety of orally administered tebipenem pivoxil hydrobromide (TBP-PI-HBr) compared to intravenously administered imipenem-cilastatin in patients with complicated urinary tract infection (cUTI) or acute pyelonephritis (AP). 

OTAC 012
An International Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of Anti-Coronavirus Hyperimmune Intravenous Immunoglobulin for the Treatment of Adult Outpatients in Early Stages of COVID-19.

219685
A seamless Phase 1/2, observer-blind, randomized, placebo-controlled, multicenter study to assess the safety and immunogenicity of a UTI vaccine when administered to adults 18 through 64 years of age and clinical efficacy when administered to females 18 through 64 years of age.  

EActive Studies - Nephrology

D6972C00002 (BaxDuo PACIFIC)

A Phase III, Randomised, Double-blind, Placebo-controlled, Event-driven Study to Assess the Efficacy, Safety and Tolerability of Baxdrostat in Combination with Dapagliflozin Compared with Dapagliflozin Alone on Renal Outcomes and Cardiovascular Mortality in Participants with Chronic Kidney Disease and High Blood Pressure

Be a Volunteer. For more information, click here.

D9440C00004 (SERENIA)

A Phase IIa, Randomised, Double-blind, Placebo-controlled, Multicentre Study to Assess the Efficacy, Safety, and Tolerability of AZD4144 in Participants with Sepsis-associated Acute Kidney Injury (SERENIA).

Completed Studies - Nephrology

BaxDuo-Arctic
A Phase III, Randomised, Double-blind Study to Assess the Efficacy, Safety, and Tolerability of Baxdrostat in Combination with Dapagliflozin Compared with Dapagliflozin Alone on Chronic Kidney Disease (CKD) Progression in Participants with CKD and High Blood Pressure.

Active Studies - Oncology

222730 (BEHOLD-1)

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5733584 for Injection in Subjects with Advanced Solid Tumors.

Be a Volunteer. For more information, click here.

Studies with Closed Enrollment - Oncology

eVOLVE-Lung02
A Phase III, Two-Arm, Parallel, Randomized, Multi-Center, Open-Label, Global Study to Determine the Efficacy of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer (mNSCLC) (eVOLVE-Lung02)

Active Studies - Pulmonology

D9181C00002 (UMBRIEL)

A Phase IIb, Multicentre, Double-blind, Placebo-controlled Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adult Participants With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids (UMBRIEL).

Be a Volunteer. For more information, click here.

D5241C00007 (JOURNEY)

A Randomised, Double-blind, Placebo-controlled, Parallel Group, Multicentre, Phase III Study to Evaluate the Efficacy and Safety of Tezepelumab in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (JOURNEY).

Be a Volunteer. For more information, click here.

Completed Studies - Pulmonology

AJAX
A Phase 2a Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AZD4604 Twice Daily for Twelve Weeks in Adult Patients with Moderate-to-Severe Asthma uncontrolled on Medium-High Dose ICS-LABA.

FLASH
A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Studyto Assess Efficacy and Safety of Atuliflapon Given Orally Once Daily for Twelve Weeks in Adults with Moderate to Severe Uncontrolled Asthma. 

Completed Studies - Pediatrics

PSUMMIT Jr
Phase III
To evaluate the efficacy, pharmacokinetics, safety and immunogenicity of subcutaneously administered ustekinumab in pediatric participants with active juvenile psoriatic arthritis (PSUMMIT Jr).
Participant requirements: Pediatric participants aged ≥5 to <18 years with active JPsA.
Study duration: 13 months (follow-up up to 17 months).

Completed Studies - HIV and STDs

Gsk B Focus 219231
Phase III
A Multicenter, Randomized, Double-Blind, Placebo-controlled Study to Assess the Efficacy and Safety of Treatment with Bepirovirsen in Participants living with Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection on Antiretroviral Treatment.













Escribe un mensaje…

Studies with Active Enrollment - Metabolism / Endocrinology

K9531-3103 (KaiNETIC-1)

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living with Obesity or Overweight with Weight-Related Comorbidities Who Do Not Have Diabetes.

Be a Volunteer. For more information, click here.

K9531-3104 (KaiNETIC-2)

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living with Obesity or Overweight and Diabetes.

Be a Volunteer. For more information, click here.

NN9490-8037 (AMBIENCE)

Use of zenagamtide for the reduction of the risk of major adverse cardiovascular events in people with established atherosclerotic cardiovascular disease and overweight or obesity (AMBIENCE).

Be a Volunteer. For more information, click here.